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Abstract
Aim:  3Evidence  indicates  that  the  comorbidity  of  dementia  with  diabetes  and
depression may affect most cognitive functions. Our chief interest was to examine the
patterns of cognitive functioning in individuals diagnosed with dementia, diabetes, and
depression  as  compared  with  dementia  plus  diabetes  (DDM),  or  dementia  plus
depression (DD) and healthy controls.
Methods: We included 207 participants with dementia (age 60+), 83 with Alzheimer’s
disease (AD), 66 vascular dementia (VaD), and 58 mixed dementia (AD/VaD). The Mini-
Mental  State Examination (MMSE) was used for global  neuropsychological  assess‐
ment, and the Center for Epidemiologic Studies Depression Scale for symptoms of
depression. Diabetes was confirmed by medical diagnosis. Results: Analysis showed
differences in cognitive functioning among the groups with statistical  significance.
Notably, there was greater cognitive dysfunction in patients with diagnosis of dementia
and depression  than  in  controls,  but  the  difference  was  reduced in  patients  with
comorbid dementia diabetes. Subsequent comparisons indicated that vascular dementia
with  comorbid  depression  and  diabetes  presents  significantly  inferior  cognitive
performance than those with dementia alone or the control group.
Conclusions: These results suggest that dementia, when combined with depression or
diabetes, adversely affects cognitive performance. These findings highlight the
importance of identifying depression among diabetics and patients with dementia.
Keywords: dementia, depression, diabetes mellitus, cognitive function, Mexican pop‐
ulation
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
One of the most common neurological conditions that affect older adults is dementia1. In
addition, public health reports in the United States show that one of the most frequent physical
illnesses found in older adults is diabetes2. Dementia affects approximately 6–10% of people
65 years or older [1], and this prevalence rate increases with age. Neuropsychological impair‐
ment associated with dementia includes poor judgment, difficulty with calculation, and
getting lost while driving [2]. Older patients with both dementia and depression typically show
impairment in the domains of attention, memory, and psychomotor speed [3]. On the other
hand, diabetes affects about 20% of people older than 65 years [4]. Patients treated for type II
diabetes show cognitive deficits on brief cognitive screening [5], and subtle decrements in
verbal memory and processing speed (mean difference in z scores -0.37 and -0.25 respectively)
on in‐depth cognitive testing. This suggests that diabetes is a significant risk factor for dementia
[6]. Depression has been estimated to affect 1–5% of community‐dwelling older adults [7].
Depression is common in dementia, with substantial variability in the reported base‐rate
ranging from 20 to 40% [4, 8, 9], and it is a probable risk factor for both vascular dementia
(VaD) and Alzheimer’s disease (AD) [10]. As for diabetes, the prevalence of depression is three
times higher in these patients than in individuals free of diabetes (OR = 2.9, 95% CI 2.3–3.7) [10].
Diabetes and depression exhibit a closely linked bi‐directional relationship: between 15 and
20% of people with diabetes will develop clinical depression, while depression is two to three
times more common among people with diabetes compared to those without. Comorbid
depression and diabetes have a 2.7‐fold increased risk for dementia [11].
Taking these factors into account, our chief interest was to compare cognitive function in
individuals diagnosed with dementia with comorbid diabetes and depressive symptoms,
alone or combined, compared to those with dementia alone, and against healthy controls.
2. Methods
2.1. Subject
All subjects from that study come from the Study on Aging and Dementia in Mexico (SADEM).
SADEM was a cross‐sectional study conducted to determine the prevalence of MCI and
dementia, between September 2009 and March 2010. Individuals age 60 years and older were
invited into the study through a random sampling of the eligible population registered within
24 family medicine units from the Instituto Mexicano del Seguro Social (IMSS) encompassing
all of Mexico City. All subjects were beneficiaries (users and non‐users) of the IMSS. The
inclusion criteria for SADEM were 1) community‐dwelling individuals aged 60 years and
older, living in Mexico City, 2) registered with IMSS; and 3) accepting to take part in the study
through informed consent. We excluded individuals 1) resident in other states; 2) living in an
institution; 3) altered mental status secondary to delirium; 4) died before study start; 5)
currently taking antipsychotic medication (other psychotropic medications including antide‐
pressants were allowed because of the potential negative impact of non‐treatment on cogni‐
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tion); and 6) those who refused to participate or who after two attempted visits could not be
located. All participants were assessed at doctor’s office by a geriatric specialized in geriatric
cognitive disorders. The diagnosis of dementia was performed during the study SADEM and
was based on the DSM‐IV. All subjects were clinically assessed. Final diagnoses were assigned
by a consensus expert panel made up of neuropsychologists, neurologists, and geriatricians
[12]. All subjects participating in the study, or their caregivers, gave signed informed consent.
The research protocol was reviewed and approved by The National Commission of Scientific
Research as well as by the IMSS Ethics Commission (registration number 2010‐785‐005).
In this way for 3D study, we included all patients diagnosed with dementia vascular,
Alzheimer disease, or both, diagnosed during the study SADEM, both sexes. Subjects were
excluded if they had a) problems with vision, b) poor auditory capacity, c) history of alcohol
abuse, d) Parkinsonism or meningioma, and e) incomplete assessment scales or neurological
examination. Finally, 330 patients were included and stratified into following groups: a)
patients with only dementia: Alzheimer (AD), vascular (VaD) and mixed (MD) (1D†), b)
patients with only depression (1D†), c) patients with only diabetes mellitus (1D†), d) patients
with AD and diabetes mellitus (2D†), e) patients with AD and depression (2D†), f) patients
with VaD and diabetes mellitus (2D†), g) patients with VaD and depression (2D†), h)
patients with MD and diabetes mellitus (2D†), i) patients with MD and depression (2D†), j)
patients with AD and diabetes mellitus and depression (3D†), k) patients with VaD and
diabetes mellitus and depression (3D†), and l) patients with MD and diabetes mellitus and
depression (3D†).
2.2. Dementia evaluation
Dementia case newly recognized was conducted in two steps. First all participants of SADEM
study were screened with the Mini‐Mental State Examination (MMSE) [13]. All participants
with a cutoff ≤24 adjustment for educational level in an aging Mexican population were
underwent a battery of neuropsychological measures and a standardized neurological
examination. We used the Clinical Dementia Rating or CDR to quantify the severity of
symptoms of dementia [14]. Complete details of the evaluation and diagnostic procedures
have been described earlier [12]. The final diagnosis of dementia was determined by consensus
expert panel review including neuropsychologists, neurologists, and geriatric physicians. Each
diagnosis was based on based on the Diagnostic and Statistical Manual of Mental Disorders
criteria for dementia [15], (DMS‐IV‐R) criteria for dementia. Once dementia was diagnosed,
subjects were further grouped according to whether they met the National Institute for
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS‐ADRDA) [16], and/or the National Institute of
Neurological Disorders and Stroke Association Internationale Pour la Recherche et l’Enseigne‐
ment en Neurosciences (NINDS‐AIREN) criteria [17]. Diagnoses fell into three categories: a)
probable Alzheimer’s disease (AD), b) vascular dementia (VaD), and c) mixed type dementia
(MD) and were ascertained using a two‐step procedure: (1) diagnosis of dementia and (2)
association of cognitive impairment to lesions of vascular of origin. The criteria for diagnosis
of MD were that the course was suggestive of AD, and in addition, there were focal neurologic
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symptoms suggestive of ischemia. The presence of vascular risk factors alone, in a patient with
otherwise clinically typical AD, was not enough to support a diagnosis of MD. Hence, patients
suspected of MD were subjected to all procedures for diagnosis.
2.3. Control subjects
The control group consisted of 134 subjects healthy from the SADEM study, which did not
meet MCI or dementia criteria, they had a CDR score of zero, and a memory test performance
<1.5 standard deviations from the mean for age. There were no significant differences between
controls and cases for age or years of education (p > 0.01).
2.4. Cognitive measure
Cognitive testing was performed on all the patients in whom MMSE [14] and was used to
evaluate global cognitive performance. For the purpose of the present study, the 11 MMSE
subtests and the global MMSE score were considered independently: spatial orientation (state,
county, town, place, and floor=5 points), temporal orientation (year, season, month, day, and
date=5 points), immediate memory (immediately repeating three words=3 points), attention/
concentration (If the participants had education as serially subtracting 7, beginning with 100,
or, alternatively, spelling the word world backward for the participants without education=5
points), delayed recall (recalling the previously repeated three words=3 points), language
(naming two items=2 points), verbal repetition (repeating a phrase=1 points), reading a sentence
(reading aloud and understanding a sentence=1 points), writing a sentence (1 points), verbal
comprehension (following a three‐step command=3 points), and constructional praxis (copying a
design=1 points). [The MMSE is thoroughly familiar to any readership in geriatrics or neurol‐
ogy. You would only need to specify the above if you were intending to present subscores.
That might be a good idea if you do not have access to the neuropsychological scores].
2.5. Depression
In addition to neuropsychological tests, depression symptoms were evaluated using the Center
for Epidemiologic Studies Depression Scale (CES‐D), a validated 20‐item scale consisting of
four factors: depressive affect, somatic complaints, positive affect, and interpersonal relations.
Scores on the CES‐D ranged from 0 to 60, where 0–15 is indicative of absence of depression,
and scores of 16–60 are indicative of depressive symptomatology [18]. The presence of
depression was corroborated with the self‐reported treatment with antidepressants, selective
serotonin reuptake inhibitors (SSRI—i.e., paroxetine, sertraline, fluoxetine, venlafaxine,
citalopram), or tricyclic antidepressants at any time during the four‐month preceding the
interview.
2.6. Diabetes assessment
Diagnosis of diabetes mellitus was based on the patients’ self‐report to the question, “Are you
taking medication for diabetes?” These diabetes diagnoses were then confirmed by blood
glucose measurements, a fasting plasma glucose concentration >7.0 mmol/l (whole blood
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>6.1 mmol/l) and hemoglobin A1c (HbA1c) (<48 mmol/mol (6.5%), and treatment. All patients
in this study were receiving treatment for diabetes, and 90% of patients were taking sulfony‐
lureas for controlling diabetes with the remaining 10% on insulin therapy.
2.7. Statistical analyses
We examined effects of dementia by type, depression, and diabetes by themselves. All
comparisons were performed with MANOVAs that are being conducted using a Bonferroni
correction of m [19], with dementia (AD, VaD, mixed), depression (yes/no), and diabetes
mellitus (yes/no) as between‐subject factors. The same MANOVAs models were then used
within each diagnostic group (AD, VaD, MD). Main effects and statistically significant
difference between groups were assessed by F‐test [20]. Additionally, a complementary
analysis to better interpret the results was carried‐out using the standardized mean effect sizes
(Hedges’ g). Hedges’ g is calculated on the basis of the standardized mean difference effect
size, which uses the pooled within‐groups SD but corrects for bias from small sample sizes.
These effect sizes indicate the mean difference between two variables expressed in standard
deviation units. Hedges’ g is a conservative estimate of effect size, which typically is
interpreted by Cohen’s d guidelines (small effect=0.20, medium effect=0.50, large effect=0.80)
[21]. A positive effect size indicates that the MMSE score in the control group was superior to
the diagnostic groups, whereas a negative effect size indicates that the diagnostic groups
outperformed the control.
3. Results
Table 1 presents the descriptive statistics (mean ± SD) of diagnostic groups. First of all, the
MANOVA models revealed that the interaction effects were not significant on sex, age, and
education (p < 0.005). When considering the main effect of the 2D† in the MMSE score, the
MANOVAs demonstrated significant effect on diabetes mellitus and depression, AD‐depres‐
sion, and AD‐diabetes mellitus, similarly MD‐diabetes mellitus, (p < 0.005). With the complete
model, we can identify significant differences between the means of the diagnostic groups (F:
39.36, p: 0.000, R2: 0.614), indicating significant differences between the three dementias and
cognitive performance.
For each diagnostic groups, we measure cognitive functioning (MMSE total scores) by
calculating the difference of mean. We then convert the difference to a standardized effect size
by dividing it by the pooled standard deviation for the diagnostic groups. These results are
shown in Table 2. The margin of error (for a 95% confidence interval) for each estimate is
shown. For example, the global cognitive functioning measured in effect size from group AD‐
depression is -3.02 standard deviation. Because the margin of error for this estimate is 0.28, the
lower bound of its 95% confidence interval is -3.54, and the upper bound is -2.46. The cognitive
performance in Table 2 exhibits a strikingly consistent pattern for combination of all three
types of dementia with diabetes. Global cognitive functioning is largest in the groups with AD
and then decline steadily into the groups with VaD and MD.
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MMSE Ages Education Sex
n Mean SD P of
corrected
model
ages
Mean SD P Mean SD P  Male
(%)
 Fe‐
male
(%)
 P R2
Control group
(0D †)
134 30.2 3.3  0.00 71.8 7.6 0.009.1 5.5 0.00 46.5 53.5 0.00 0.37
Group diabetes mellitus
(1D †)
28  29.2 5.1  0.00 71.6 7.0 0.037.0 6.2 0.00 52.5 47.5 0.00 0.67
Group depression
(1D †)
84  30.2 3.2  0.00 69.4 6.7 0.008.9 5.9 0.00 56.5 43.5 0.00 0.33
Group diabetes
mellitus and depression (2D
†)
10  28.7 6.7  0.01 67.8 8.1 0.016.9 6.2 0.35 45.6 54.4 0.02 0.72
Group AD * (1D †) 37  18.7 7.4  0.03 76.3 8.7 0.036.4 5.1 0.11 66.3 33.7 0.10 0.24
Group
AD‐depression
(2D †)
25  18.7 5.3  0.03 78.2 8.9 0.035.8 5.1 0.68 75.0 25.0 0.07 0.35
Group AD‐diabetes
mellitus (2D †)
13  21.4 4.5  0.52 74.5 10.0 0.424.1 3.7 0.76 23.8 76.2 0.00 0.21
Group AD‐diabetes
and depression (3D †)
8  21.8 4.2  0.95 74.3 7.4 0.907.0 6.6 0.71 75.0 25.0 0.86 0.08
Group with
VaD * (1D †)
24  21.5 4.2  0.48 76.0 8.5 0.246.7 6.6 0.89 55.2 44.8 0.41 0.12
Group VaD‐Depression
(2D †)
19  19.7 6.2  0.53 80.0 8.3 0.185.6 4.2 0.86 57.1 42.9 0.10 0.53
Group VaD‐diabetes
mellitus (2D †)
10  20.8 6.5  0.37 78.3 6.6 0.235.9 5.0 0.33 45.8 54.2 0.10 0.39
Group VaD‐diabetes
and depression (3D †)
14  20.8 6.0  0.46 76.7 7.9 0.416.6 6.5 0.30 57.1 42.9 0.88 0.22
Group MD * (1D †) 12  17.4 5.8  0.51 76.7 8.9 0.225.8 6.8 0.64 41.4 58.6 0.76 0.24
Group
MD‐depression
(2D †)
7  15.3 7.7  0.47 77.3 9.8 0.229.7 6.0 0.48 21.1 78.9 0.30 0.39
Group MD‐diabetes
mellitus (2D †)
27  18.0 4.9  0.67 77.8 9.2 0.456.6 5.4 0.30 26.3 73.7 0.01 0.07
Group MD‐diabetes
and depression
(3D †)
12  17.9 6.4  0.38 78.9 7.8 0.877.5 4.9 0.26 16.7 83.3 0.13 0.31
MANOVA (complete model): sum of squares = 14913.79, gl: 18, F: 39.36, p: 0.000, R2: 0.614.
MMSE: mini‐mental state examination; 0D: group without “D”, 1D group with one D, 2D group with 2D, 3D group
with 3D; C‐E: mean of control group—mean of group (0D or 1D or 2D or 3D).
*Dementia: Alzheimer (AD), vascular (VaD), and mixed (MD).
†D is dementia or diabetes mellitus or depression.
Table 1. Demographic characteristic of diagnostic groups.
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Type of dementia Mean
difference
(C–E)
p‐Value
for mean
difference
(2‐tailed T‐
test)
95% confidence
interval
for effect size
Effect
size
Bias
corrected
(Hedges)
Standard
error of
effect size
estimate
95% confidence
interval
for effect size
Lower  Upper Lower Upper
Control group (0D †)
Group diabetes
(1D †)
-1.04 0.303 -2.55 -9.89 -0.28 -0.28 0.21 -0.69 0.13
Group depression
(1D †)
-0.05 0.944 -0.94 0.85 -0.01 -0.01 0.14 -0.29 0.26
Group diabetes and
depression
(2D †)
-1.54 0.332 -3.89 0.81 -0.42 -0.42 0.33 -1.07 0.22
Group AD *
(1D †)
-11.55 0.000 -13.20 -9.89 -2.56 -2.55 0.23 -3.00 -2.09
Group AD‐
depression
(2D †)
-11.56 0.000 -13.21 -9.91 -3.02 -3.00 0.28 -3.54 -2.46
Group AD‐diabetes
(2D †)
-8.81 0.000 -11.78 -6.84 -2.57 -2.55 0.33 -3.19 -1.91
Group
AD‐diabetes and
depression
(3D †)
-8.43 0.000 -10.86 -6.01 -2.50 -2.49 0.39 -3.26 -1.72
Group with VaD *
(1D †)
-8.78 0.000 -10.29 -7.26 -2.54 -2.52 0.26 -3.04 -2.01
Group VaD‐
depression (2D †)
-10.52 0.000 -12.35 -8.69 -2.78 -2.77 0.29 -3.34 -2.20
Group
VaD‐diabetes
(2D †)
-12.20 0.000 -11.78 -7.11 -2.62 -2.60 0.36 -3.31 -1.89
Group
VaD‐diabetes and
depression
(3D †)
-9.48 0.000 -11.50 -7.47 -2.61 -2.60 0.32 -3.22 -1.97
Group MD * (1D †) -13.78 0.000 -15.95 -11.61 -3.78 -3.76 0.37 -4.49 -3.03
Group MD‐
depression (2D †)
-14.97 0.000 -17.74 -12.10 -4.14 -4.11 0.46 -5.21 -3.21
Group
MD‐diabetes (2D †)
-12.20 0.000 -13.71 -10.69 -3.36 -3.34 0.28 -3.89 -2.79
Group
MD‐diabetes and
depression
(3D †)
-12.32 0.000 -14.49 -10.15 -3.38 -3.36 0.36 -4.07 -2.66
MMSE: mini‐mental state examination; 0D: group without “D”, 1D group with one D, 2D group with 2D, 3D group
with 3D; C‐E: mean of control group—mean of group (0D or 1D or 2D or 3D).
*Dementia: Alzheimer (AD), vascular (VaD), and mixed (MD).
†D is dementia or diabetes mellitus or depression.
Table 2. Mean and effect sizes of the MMSE by type of dementia.
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We illustrate such cognitive performance gaps in Figure 1, which shows differences in terms
of effect sizes, that is, the difference in mean scores divided by the standard deviation of scores
for all groups. When comparing among the dementia groups, we observed that patients with
AD presented better cognitive performance than patients with the diagnosis of VaD and MD,
while patients with MD‐depression had worse cognitive performance than patients with any
type of dementias and diabetes and depression. Which confirms the finding that the worst
cognitive performance is evident in the groups od MD and depression (Figure 1).
Figure 1. Hedges’ g of the MMSE by type of dementia. Alzheimer (AD), vascular (VaD), and mixed (MD) and “#” is
the number of “D” a group has (0 or 1 or 2 or 3), and the letter “D” is dementia or diabetes mellitus or depression.
4. Discussion
To our knowledge, this is the first study to attempt to examine the specific patterns of per‐
formance on measures of neuropsychological functioning among those with diagnosis of
dementia with co‐existing diabetes and depression. We found supporting evidence showing
the variation in the neuropsychological functioning between individuals with 3Ds in contrast
to dementia patients with either comorbid depression or diabetes. Overall, patients with
dementia with coexisting diabetes and depression had greater cognitive impairment relative
to dementia only, or healthy controls. There was a non‐significant trend for cognitive scores
of dementia and depression group to fall between the dementia with diabetes groups. These
results illustrate the importance of controlling for depression and diabetes when diagnosing
cognition. Some studies suggest that depression is a risk factor for dementia and depression
treatment may be a causal factor for dementia [22]. Furthermore, depression may increase
vulnerability to and/or exacerbate existing cognitive deficits [23]. Additionally, Ritchie et al.
[24] examined the association between depression and diabetes and report that 36.8% of the
patients with dementia have depression, while only 10.6% have diabetes. Similar reports [25]
show that 23.7% of patients with dementia have dementia and depression. While the precise
neurobiological mechanisms underlying depression and cognitive abnormalities in type 2
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diabetes are unknown, both cognitive impairment and diabetes have been observed among
older adults with major depression. In our study, patients with dementia and diabetes had
lower scores on cognitive performance relative to healthy controls, which is consistent with
previously reports in other populations.
Overall, type 2 diabetes has been associated with mild cognitive deficits, most frequently in
the domains of verbal memory, processing speed, and to a lesser degree, executive functioning
(see review) [5]. Another study suggests that there is a protector effect of insulin on surface
plasma insulin receptors, although it is possible that the improvement of cognitive function is
due to better glucose control rather than a direct effect on the neurons [27]. However, meth‐
odological and study design differences, such as variations in sampling, assessment instru‐
ments, degree of diabetes severity, and the presence of comorbid illnesses, have resulted in
inconclusive results. Consistent with the literature on diabetes research, research examining
the relationship between depression and cognitive functioning is filled with mixed results, as
mentioned above. There is evidence suggesting that the pattern of cognitive impairment varies
by depression subgroup or severity (e.g., major versus minor depression) [30, 31]. In general,
depression has been linked with a range of declines in cognitive domains, including memory,
executive functioning, attention, and psychomotor speed [32].
The present study differs from others in that previous studies typically relied only on self‐
report for depression with varying measurement instruments. In our study, we also corrobo‐
rated our depression status with the medical prescription of any antidepressant.
The present study had several limitations. First, the specific treatments of the patients with
diabetes were not verified, so that it is impossible to draw conclusions about the influence of
diabetes treatment on cognitive impairment in this sample. Time with any of the conditions
was not available, so the effect of short versus long term cannot be confirmed. In addition,
other comorbidities, especially those affecting vascular, neuronal, or metabolic status, were
not taken into account. The nature of the design does not allow for explanation of the mecha‐
nisms of the relationships observed. Another important limitation of this study is that we
included only the MMSE, which is not a diagnostic instrument, to assess the cognitive function.
We understand this test is widely used for its ability to follow cognitive changes over time [33].
Despite these limitations, with our large sample size, rigorous study design, and broad
socioeconomic, and educational characteristics of our participants, we believe that it is possible
to make valid inferences to the elderly population residing in Mexico City.
The patients with triple diagnoses of dementia, depression, and diabetes demonstrated greater
cognitive dysfunction relative to those with double or single diagnosis of dementia. Additional
research is needed to unravel this relationship, as to whether the cognitive impairment accrued
in patients with DDD. These findings highlight the importance of identifying depression
among diabetics and patients with dementia. Since depression is readily treatable, remission
should lead to improved cognitive function and quality of life. The role of neuropsychology
is expanding due to the increasing demand for differential diagnosis and to draw conclusions
about patients’ abilities to function independently. Further research is necessary to define and
recognize patients with dementia with comorbid conditions.
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